Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2019

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

pharmaceutical companies pharma intelligence

The partner of choice for pharmaceutical companies

Bring game-changing drugs to market more efficiently. We’ll help you understand the competition to hone in on your strategies to improve healthcare and patient outcomes.

Get drugs to market faster

adevelopment partner pharma intelligence

The right drugs developed at the right time transform pharmaceutical and biotechnology companies and improve patients’ lives. But the process is long and complex, taking place in an ever-changing, intensely competitive arena.

How we help
As the trusted pharma research partner of the top 50 global pharmaceutical companies, we provide reliable, timely intelligence and insights to help you every step of the way during drug development.

We can help you:

Optimize your clinical trials
Stay ahead of the competition by fully understanding future patient needs
Tailor your portfolio and commercial strategies to market needs
Identify opportunities and overcome potential threats across your pipeline
Stay current and be prepared for market shifts
Access historical success rates, and development and regulatory durations from a large number of perspectives

Our unique strengths

Identify market opportunities

Understand where future drug and development opportunities lie with access to the industry’s leading forecasts and behind-the-headlines analysis.

Capitalize on treatment trends

Keep on top of global trends and access source information on the impact of developing technologies.

Approach reimbursement proactively

Our reimbursement analysis can assist your business planning – both at the early stages of product development and long after product launch.

View competitor activity

Get unique competitor insight with our detailed reviews of your competitors’ clinical trials and our ability to track all drugs in development.

View more
View Less

Relevant products

Awareness

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Effective reporting

HBW Insight: Health, Beauty and Wellness

The single most comprehensive consumer healthcare information source covering regulatory, legislative, legal and commercial news across the over the counter medicines, vitamins and dietary supplements, and cosmetics industries.

Key benefits:

Get a global view
Be the first to know
Go beyond the news

Generics Bulletin

A well-respected and trusted industry source for the last 15 years, Generics Bulletin from Informa Pharma Intelligence provides in-depth news and analysis on issues that matter most to businesses across the generics, biosimilars and value-added medicines industries.

Key benefits:

Ask-the-Analyst™ Service
A powerful online platform
In-depth content coverage

View all content

Generics Bulletin

Hikma Snaps Up Insys Sprays As Part Of US Drive Towards Differentiation

By Aidan Fry 15 Aug 2019

By acquiring global rights to epinephrine and naloxone nasal spray candidates from Insys, Hikma is following its strategy of moving its non-injectable Generics business segment in the US towards differentiated products.

Topic Business strategies

View article
Scrip

An AdComm After All: Amarin's Vascepa Labeling Update Now Delayed By FDA

By Mandy Jackson 15 Aug 2019

The US FDA informed the company it will convene an advisory committee meeting to review the REDUCE-IT sNDA for the proprietary fish oil pill, delaying the approval by at least three months and surprising investors.

Topic FDA Drug approval

View article
Scrip

Taltz Tops Tremfya In Head-To-Head Psoriasis Study On Complete Skin Clearance

By Jessica Merrill 15 Aug 2019

Lilly's IL-17A inhibitor ixekizumab outperformed J&J's IL-23 inhibitor guselkumab on achieving complete skin clearance in moderate-to-severe psoriasis patients at 12 weeks in a head-to-head trial.

Topic Clinical trials

View article
Generics Bulletin

Chirag Patel And Chintu Patel Return As Co-CEOs Of Amneal

By David Wallace 14 Aug 2019

Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.

Topic Company analysis

View article
Scrip

Oncology Market Leaders Maintain Their Upper Hand

By Jessica Merrill 14 Aug 2019

Drugs like Ibrance and Lynparza show that in the cancer market, it can be hard for new entrants to catch early standouts.

Topic Drug development landscape Drug review

View article
Scrip

The Chinese Pharma Market: Insights in turbulent times

12 Aug 2019

With the continuation of the US-China trade standoff, the rapid increase in R&D costs and a gruelling centralized bidding process, foreign pharma firms have a lot on their plates in China. Gain insight on these key challenges through this Scrip article pack

Topic Business strategies

Single report
Trialtrove

Trialtrove 2018 Completed Clinical Trials Snapshot

12 Aug 2019

Get a visual snapshot of how the industry pipelines are faring with our 2018 Completed Trials snapshot. This graphic analysis paints a clear picture of the state of clinical trial completions, while pointing to some important changes that are emerging.

Topic Clinical trials Drug development landscape

Single report
Generics Bulletin

Reddy's Will Look For Acquisitions Under New CEO Israeli

By Aidan Fry 09 Aug 2019

With Erez Israeli set to step up from COO to CEO, Dr Reddy’s is looking to leverage its lack of debt and strong cash flow in the mergers and acquisitions arena.

Topic Business strategies

View article
HBW Insight

Japan's New Rx-To-OTC Procedure Exacerbating Switch Blockage Says JSMI

By David Ridley 07 Aug 2019

Japan's new Rx-to-OTC switch procedure has exacerbated a "switch lag" compared with developed countries, says Japan Self-Medication Industry senior adviser Toshi Tominaga in an exclusive interview with HBW Insight. Tominaga proposes improvements such as self-care education for consumers and drug usage advice included by firms in switch applications to help balance the risk-benefit decisions of expert judges.

Topic Policy and regulation

View article
Trialtrove

2018 Completed Trials: State of Industry-Sponsored Clinical Development

06 Aug 2019

The landscape of trials initiated by industry sponsors is one metric that informs about the R&D health of the biopharma industry. Looking specifically at trial completions adds a layer of granularity to the trials landscape and provides valuable perspective on how well industry pipelines are faring. As Informa Pharma has done for the past four years, we report the results from our analysis of the landscape of clinical trials completed during 2018.

Topic Drug development landscape

Single report
Scrip

Love From Shanghai: Upjohn Started Here But Will It Stay Post-Mylan?

By Brian Yang 05 Aug 2019

Opened with a big splash just two months ago in a brand new headquarters in Shanghai, Pfizer's Upjohn established products subsidiary is now merging with Mylan to create the world's largest generics group, stirring up local concerns that the focus could shift from China back to the US.

Topic Company analysis Business strategies

View article
Scrip

At Pfizer, A Split A Decade In The Making

By Jessica Merrill 05 Aug 2019

Pfizer's ambitious plans to spin out its Upjohn branded and generics business will result in a smaller, innovation-focused pharma. The decision comes after nine years of back-and-forth about whether the move would unlock value.

Topic BioPharmaceutical Company analysis

View article
Generics Bulletin

Sandoz Reveals Biosimilar Denosumab Program

By David Wallace 30 Jul 2019

As Sandoz reported its second-quarter financial results, the firm revealed details of a previously unannounced development program for biosimilar denosumab.

Topic Company analysis Biosimilars

View article
Scrip

A New Day Dawns For Avastin

By Jessica Merrill 30 Jul 2019

The launch of Mvasi will be the first biosimilar version of Avastin in the US, a huge blockbuster for Roche approved for multiple cancer indications. Scrip looks at the development and commercial history of Avastin since its FDA approval in 2004.

Topic BioPharmaceutical Company analysis

View article
Scrip

Sunset Begins For Roche's Herceptin As Amgen/Allergan Biosimilar Launches

By Jessica Merrill 30 Jul 2019

Amgen and Allergan launched the first US biosimilar for Roche's Herceptin – and the Swiss pharma's Avastin – at a 15% discount to the brand-name products' list prices. Scrip's infographic reviews Herceptin's past and its future competitors.

Topic Biosimilars

View article

Latest headlines

Scrip

23 Aug 2019

DREAMM-2 Put GSK’s BCMA Drug In Pole Position In Multiple Myeloma

Link
Scrip

23 Aug 2019

Lupin Rationalizes Japan Operations, Sheds Injectables Business

Link
Scrip

23 Aug 2019

Deal Watch: Themis Leverages Measles Vector Platform In Collaboration With Merck & Co.

Link
Scrip

23 Aug 2019

Finance Watch: Five More Biopharmas Enter US Queue Even As IPO Returns Dip

Link
Scrip

22 Aug 2019

Longer Intervals OK With ViiV's Injectable Anti-HIV Regimen

Link
Scrip

22 Aug 2019

Executives On The Move: Top Hires At Ribon And SQZ And Roche Promotes A Business Leader

Link
Scrip

22 Aug 2019

Retrophin's Focus Shifts After Phase III PKAN Drug's Failure

Link
Scrip

22 Aug 2019

Finance Watch: Chinook Debuts With $65m For Precision Kidney Disease Medicines

Link
Scrip

22 Aug 2019

AstraZeneca Buys Priority Review Voucher With Two Big Filings On The Horizon

Link
Scrip

22 Aug 2019

NICE Head Sir Andrew Dillon To Stand Down

Link
Scrip

22 Aug 2019

Novo Nordisk's Ultra-Fast Acting Insulin Cleared For Pediatric Use In EU

Link
Scrip

21 Aug 2019

Bayer Says $7.6bn Farewell To Animal Health As It Sells Unit To Elanco

Link
Scrip

21 Aug 2019

AstraZeneca’s Imfinzi-Treme Checkpoint Inhibitor Combination Fails Again In NSCLC

Link
Scrip

21 Aug 2019

Big Pharma Nibbles As Turkey’s Localization Policy Yields Limited Results

Link
Scrip

21 Aug 2019

Oncorus Raises $79.5m To Take Its First Oncolytic Virus Into The Clinic

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

The partner of choice for pharmaceutical companies

Get drugs to market faster

Our unique strengths

Identify market opportunities

Capitalize on treatment trends

Approach reimbursement proactively

View competitor activity

Relevant products

Below are the Product List

Awareness

HBW Insight: Health, Beauty and Wellness

Generics Bulletin

Pharma Intelligence latest insights

Latest headlines

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Pharma Report Store